Identifying potential endocrine disruptors among industrial chemicals and their metabolites - development and evaluation of in silico tools

Chemosphere

Volumn 139, Issue , 2015, Pages 372-378

  Rybacka, Aleksandra ^a   Rudén, Christina ^b   Tetko, Igor V ^c   Andersson, Patrik L ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b STOCKHOLM UNIVERSITY   (Sweden)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Androgen; Endocrine disruptor; Estrogen; Metabolism; QSAR; Transthyretin

Indexed keywords

BINDERS; COMPUTATIONAL CHEMISTRY; INDUSTRIAL CHEMICALS; INFORMATION DISSEMINATION; METABOLISM; METABOLITES;

ANDROGEN; ENDOCRINE DISRUPTOR; ESTROGEN; QSAR; TRANSTHYRETIN;

ENDOCRINE DISRUPTERS;

ENDOCRINE DISRUPTOR; INDUSTRIAL CHEMICAL; PREALBUMIN; THYROXINE; ANDROGEN RECEPTOR; ESTROGEN RECEPTOR; PROTEIN BINDING;

ACCURACY ASSESSMENT; ANDROGEN; BIOACTIVITY; ENDOCRINE DISRUPTOR; ESTROGENIC COMPOUND; HORMONE; IDENTIFICATION METHOD; INDUSTRIAL PRACTICE; METABOLISM; METABOLITE; MODEL TEST; PRIORITIZATION; SERUM;

ACCURACY; ARTICLE; BIOTRANSFORMATION; BLOOD LEVEL; COMPUTER MODEL; CONTROLLED STUDY; EVALUATION STUDY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; METABOLIC ACTIVATION; METABOLISM; METABOLITE; NONHUMAN; THYROXINE BLOOD LEVEL; BINDING COMPETITION; BIOLOGICAL MODEL; ENVIRONMENTAL MONITORING; INDUSTRY; MCF 7 CELL LINE; PROCEDURES;

BINDING, COMPETITIVE; ENDOCRINE DISRUPTORS; ENVIRONMENTAL MONITORING; HUMANS; INDUSTRY; MCF-7 CELLS; MODELS, BIOLOGICAL; PREALBUMIN; PROTEIN BINDING; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN;

EID: 84942532224     PISSN: 00456535     EISSN: 18791298     Source Type: Journal    
DOI: 10.1016/j.chemosphere.2015.07.036     Document Type: Article

References (68)

1. Branchi I., Capone F., Vitalone A., Madia F., Santucci D., Alleva E., Costa L.G. Early developmental exposure to BDE 99 or Aroclor 1254 affects neurobehavioural profile: interference from the administration route. NeuroToxicology 2005, 26:183-192.
2. Breiman L. Bagging predictors. Machine Learning 1996, 24:123-140.
3. Cao F., Li X.L., Ye L., Xie Y.W., Wang X.X., Shi W., Qian X.P., Zhu Y.L., Yu H.X. Molecular docking, molecular dynamics simulation, and structure-based 3D-QSAR studies on the aryl hydrocarbon receptor agonistic activity of hydroxylated polychlorinated biphenyls. Environ. Toxicol. Pharmacol. 2013, 36:626-635.
4. Chen H.F., Li Q., Yao X.J., Fan B.T., Yuan S.G., Panaye A., Doucet J.P. 3D-QSAR and docking study of the binding mode of steroids to progesterone receptor in active site. QSAR Comb. Sci. 2003, 22:604-613.
5. Cristofolini L., Testoni M. The importance of sample size and statistical power in experimental research. A comparative study. Acta Bioeng. Biomech. 2000, 2:3-16.
6. den Besten C., Vet J., Besselink H., Kiel G., van Berkel B., Beems R., van Dladeren P. The liver, kidney, and thyroid toxicity of chlorinated benzenes. Toxicol. Appl. Pharmacol. 1991, 111:69-81.
7. Devillers J., Marchand-Geneste N., Carpy A., Porcher J.M. SAR and QSAR modeling of endocrine disruptors. SAR QSAR Environ. Res. 2006, 17:393-412.
8. Diamanti-Kandarakis E., Bourguignon J.-P., Giudice L.C., Hauser R., Prins G.S., Soto A.M., Zoeller R.T., Gore A.C. Endocrine-disrupting chemicals: an endocrine society scientific statement. Endocr. Rev. 2009, 30:293-342.
9. Ding D., Xu L., Fang H., Hong H., Perkins R., Harris S., Bearden E., Shi L., Tong W. The EDKB: an established knowledge base for endocrine disrupting chemicals. BMC Bioinformatics 2010, 11:1-7.
10. Discovery, M., 2014. MetaSite. Molecular Discovery.
11. Du J., Qin J., Liu H.X., Yao X.J. 3D-QSAR and molecular docking studies of selective agonists for the thyroid hormone receptor beta. J. Mol. Graph. 2008, 27:95-104.
12. EC, 2014. Endocrine Disruptors Strategy - What is being done? European Commission.
13. EFSA, 2008. Conclusion on the peer review of pencazole. EFSA Scientific Report. European Food Safety Authority, pp. 1-104.
14. Jacobs M.N., Laws S., Willett K., Schmieder P., Odum J., Bovee T. In vitro metabolism and bioavailability tests for endocrine active substances: what is needed next for regulatory purposes?. ALTEX 2013, 30:331-351.
15. Jensen G.E., Nikolov N.G., Wedebye E.B., Ringsted T., Niemelä J.R. QSAR models for anti-androgenic effect - a preliminary study. SAR QSAR Environ. Res. 2011, 22:35-49.
16. Juberg D.R., Gehen S.C., Coady K.K., LeBaron M.J., Kramer V.J., Lu H.T., Marty M.S. Chlorpyrifos: weight of evidence evaluation of potential interaction with the estrogen, androgen, or thyroid pathways. Regul. Toxicol. Pharm. 2013, 66:249-263.
17. Kortenkamp, A., Martin, O., Faust, M., Evans, R., McKinlay, R., Orton, F., Rosivatz, E., 2011. State of the art assessment of endocrine disrupters. European Commission.
18. Kovarich S., Papa E., Gramatica P. QSAR classification models for the prediction of endocrine disrupting activity of brominated flame retardants. J. Hazard. Mater. 2011, 190:106-112.
19. Kruhlak N.L., Benz R.D., Zhou H., Colatsky T.J. (Q)SAR modelling and safety assessment in regulatory review. Clin. Pharmacol. Ther. 2012, 91:529-534.
20. Kuiper G.G.J.M., Carlsson B., Grandien K., Enmark E., Häggblad J., Nilsson S., Gustafsson J.-A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 1997, 138:863-870.
21. Lhasa, 2014. Meteor Nexus. Lhasa Limited.
22. Li F., Li X.H., Liu X.L., Zhang L.B., You L.P., Zhao J.M., Wu H.F. Docking and 3D-QSAR studies on the Ah receptor binding affinities of polychlorinated biphenyls (PCBs), dibenzo-p-dioxins (PCDDs) and dibenzofurans (PCDFs). Environ. Toxicol. Pharmacol. 2011, 32:478-485.
23. Li F., Xie Q., Li X.H., Li N., Chi P., Chen J.W., Wang Z.J., Hao C. Hormone activity of hydroxylated polybrominated diphenyl ethers on human thyroid receptor-beta. In vitro and in silico investigations. Environ. Health Persp. 2010, 118:602-606.
24. Li H., Ren X., Leblanc E., Frewin K., Rennie P.S., Cherkasov A. Identification of novel androgen receptor antagonists using structure- and ligand-based methods. J. Chem. Inf. Model. 2013, 53:123-130.
25. Li J., Gramatica P. Classification and virtual screening of androgen receptor antagonists. J. Chem. Inf. Model. 2010, 50:861-874.
26. Li J., Gramatica P. QSAR classification of estrogen receptor binders and pre-screening of potential pleiotropic EDCs. SAR QSAR Environ. Res. 2010, 21:657-669.
27. Li X., Wang X., Shi W., Liu H., Yu H. Analysis of Ah receptor binding affinities of polybrominated diphenyl ethers via in silico molecular docking and 3D-QSAR. SAR QSAR Environ. Res. 2013, 24:75-87.
28. Li X.L., Ye L., Wang X.X., Wang X.Z., Liu H.L., Zhu Y.L., Yu H.X. Combined 3D-QSAR, molecular docking and molecular dynamics study on thyroid hormone activity of hydroxylated polybrominated diphenyl ethers to thyroid receptors beta. Toxicol. Appl. Pharmacol. 2012, 265:300-307.
29. Li Y., Wang Y., Ding J., Wang Y., Chang Y., Zhang S. In silico prediction of androgenic and nonandrogenic compounds using random forest. QSAR Comb. Sci. 2009, 28:396-405.
30. Lill M.A., Winiger F., Vedani A., Ernst B. Impact of induced fit on ligand binding to the androgen receptor: a multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals. J. Med. Chem. 2005, 48:5666-5674.
31. Liu H.X., Gramatica P. QSAR study of selective ligands for the thyroid hormone receptor beta. Bioorg. Med. Chem. 2007, 15:5251-5261.
32. Liu R.F., Liu J., Tawa G., Wallqvist A. 2D SMARTCyp reactivity-based site of metabolism prediction for major drug-metabolizing cytochrome P450 enzymes. J. Chem. Inf. Model. 2012, 52:1698-1712.
33. Mannens, G., Van Leemput, L., Heykants, J., 1993. General metabolism of imazalil in the rat. Janssen Pharmaceutica N.V.
34. METI, 2014. Receptor Binding Assay database. Ministry of Economy, Trade and Industry (METI).
35. Murk A.J., Rijntjes E., Blaauboer B.J., Clewell R., Crofton K.M., Dingemans M.M.L., David Furlow J., Kavlock R., Köhrle J., Opitz R., Traas T., Visser T.J., Xia M., Gutleb A.C. Mechanism-based testing strategy using in vitro approaches for identification of thyroid hormone disrupting chemicals. Toxicol. Vitro 2013, 27:1320-1346.
36. OECD, 2012. OECD Work Related to Endocrine Disrupters.(accessed 03.07.15). http://www.oecd.org/env/ehs/testing/oecdworkrelatedtoendocrinedisrupters.htm.
37. Optibrium, 2014. StarDrop. Optibrium.
38. Pal R., Islam M.A., Hossain T., Saha A. Molecular modeling on structure-function analysis of human progesterone receptor modulators. Sci. Pharm. 2011, 79:461-477.
39. Papa E., Kovarich S., Gramatica P. QSAR prediction of the competitive interaction of emerging halogenated pollutants with human transthyretin£. SAR QSAR Environ. Res. 2013, 24:333-349.
40. Petrik J., Drobna B., Pavuk M., Jursa S., Wimmerova S., Chovancova J. Serum PCBs and organochlorine pesticides in Slovakia: age, gender, and residence as determinants of organochlorine concentrations. Chemosphere 2006, 65:410-418.
41. Rännar S., Andersson P.L. A novel approach using hierarchical clustering to select industrial chemicals for environmental impact assessment. J. Chem. Inf. Model. 2010, 50:30-36.
42. Rayne S., Goss C.D., Forest K., Friesen K.J. Quantitative structure-activity relationships for estimating the aryl hydrocarbon receptor binding affinities of resveratrol derivatives and the antioxidant activities of hydroxystilbenes. Med. Chem. Res. 2010, 19:864-901.
43. Roberts T.R., Hutson D., Lee P. Metabolic Pathways of Agrochemicals, Part 1: Herbicides and Plant Growth Regulators 1998, Royal Society of Chemistry, Cambridge, GBR.
44. Rybacka A., Rudén C., Andersson P.L. On the use of in silico tools for prioritising toxicity testing of the low-volume industrial chemicals in REACH. Basic Clin. Pharm. 2014, 115:77-87.
45. Serafimova R., Todorov M., Nedelcheva D., Pavlov T., Akahori Y., Nakai M., Mekenyan O. QSAR and mechanistic interpretation of estrogen receptor binding§. SAR QSAR Environ. Res. 2007, 18:389-421.
46. Shin Y.G., Le H., Khojasteh C., Hop C. Comparison of metabolic soft spot predictions of CYP3A4, CYP2C9 and CYP2D6 substrates using MetaSite and StarDrop. Comb. Chem. High Throughput Screen 2011, 14:811-823.
47. So S.S., van Helden S.P., van Geerestein V.J., Karplus M. Quantitative structure - activity relationship studies of progesterone receptor binding steroids. J. Chem. Inf. Comput. Sci. 2000, 40:762-772.
48. Soderholm A.A., Lehtovuori P.T., Nyronen T.H. Docking and three-dimensional quantitative structure-activity relationship (3D QSAR) analyses of nonsteroidal progesterone receptor ligands. J. Med. Chem. 2006, 49:4261-4268.
49. Sushko I., Novotarskyi S., Körner R., Pandey A., Rupp M., Teetz W., Brandmaier S., Abdelaziz A., Prokopenko V., Tanchuk V., Todeschini R., Varnek A., Marcou G., Ertl P., Potemkin V., Grishina M., Gasteiger J., Schwab C., Baskin I., Palyulin V., Radchenko E., Welsh W., Kholodovych V., Chekmarev D., Cherkasov A., Aires-de-Sousa J., Zhang Q.-Y., Bender A., Nigsch F., Patiny L., Williams A., Tkachenko V., Tetko I. Online chemical modeling environment (OCHEM): web platform for data storage, model development and publishing of chemical information. J. Comput.-Aided Mol. Des. 2011, 25:533-554.
50. T'Jollyn H., Boussery K., Mortishire-Smith R.J., Coe K., De Boeck B., Van Bocxlaer J.F., Mannens G. Evaluation of three state-of-the-art metabolite prediction software packages (Meteor, MetaSite, and StarDrop) through independent and synergistic use. Drug Metab. Dispos. 2011, 39:2066-2075.
51. Taha M.O., Tarairah M., Zalloum H., Abu-Sheikha G. Pharmacophore and QSAR modeling of estrogen receptor β ligands and subsequent validation and in silico search for new hits. J. Mol. Graph. Model. 2010, 28:383-400.
52. Tetko I.V. Neural network studies. 4. Introduction to associative neural networks. J. Chem. Inf. Comput. Sci. 2002, 42:717-728.
53. Todeschini R., Consonni V. Handbook of Molecular Descriptors 2000, WILEY-VCH, Weinheim.
54. Todorov M., Mombelli E., Aït-Aïssa S., Mekenyan O. Androgen receptor binding affinity: a QSAR evaluation. SAR QSAR Environ. Res. 2011, 22:265-291.
55. Toropov A., Toropova A., Diaza R., Benfenati E., Gini G. SMILES-based optimal descriptors: QSAR modeling of estrogen receptor binding affinity by correlation balance. Struct. Chem. 2012, 23:529-544.
56. Trunzer M., Faller B., Zimmerlin A. Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC-MS/MS validation. J. Med. Chem. 2009, 52:329-335.
57. Valadares N.F., Castilho M.S., Polikarpov I., Garratt R.C. 2D QSAR studies on thyroid hormone receptor ligands. Bioorg. Med. Chem. 2007, 15:4609-4617.
58. Van den Berg K.J., van Raaij J.A.G.M., Bragt P.C., Notten W.R.F. Interactions of halogenated industrial chemicals with transthyretin and effects on thyroid hormone levels in vivo. Arch. Toxicol. 1991, 65:15-19.
59. Vedani A., Descloux A.V., Spreatico M., Ernst B. Predicting the toxic potential of drugs and chemicals in silico: a model for the peroxisome proliferator-activated receptor-gamma (PPAR gamma). Toxicol. Lett. 2007, 173:17-23.
60. Vedani A., Dobler M., Lill M.A. Combining protein modeling and 6D-QSAR. Simulating the binding of structurally diverse ligands to the estrogen receptor. J. Med. Chem. 2005, 48:3700-3703.
61. Vedani A., Smiesko M., Spreafico M., Peristera O., Dobler M. VirtualToxLab (TM) - in silico prediction of the toxic (endocrine-disrupting) potential of drugs, chemicals and natural products. Two years and 2000 compounds of experience: a progress report. Altex Altern. Tierexp. 2009, 26:167-176.
62. Vorberg S., Tetko I.V. Modeling the biodegradability of chemical compounds using the Online CHEmical Modeling Environment (OCHEM). Mol. Inf. 2014, 33:73-85.
63. Weiss J.M., Andersson P.L., Zhang J., Simon E., Leonards P.E., Hamers T., Lamoree M.H. Tracing thyroid hormone-disrupting compounds: database compilation and structure-activity evaluation for an effect-directed analysis of sediment. Anal. Bioanal. Chem. 2015, 1-10.
64. Yang W.H., Shen S.D., Mu L.L., Yu H.X. Structure-activity relationship study on the binding of PBDEs with thyroxine transport proteins. Environ. Toxicol. Chem. 2011, 30:2431-2439.
65. Yi Z., Zhang A. A QSAR study of environmental estrogens based on a novel variable selection method. Molecules 2012, 17:6126-6145.
66. Yuan J.T., Pu Y.P., Yin L.H. Docking-based three-dimensional quantitative structure-activity relationship (3D-QSAR) predicts binding affinities to aryl hydrocarbon receptor for polychlorinated dibenzodioxins, dibenzofurans, and biphenyls. Environ. Toxicol. Chem. 2013, 32:1453-1458.
67. Zhang L., Sedykh A., Tripathi A., Zhu H., Afantitis A., Mouchlis V.D., Melagraki G., Rusyn I., Tropsha A. Identification of putative estrogen receptor-mediated endocrine disrupting chemicals using QSAR- and structure-based virtual screening approaches. Toxicol. Appl. Pharmacol. 2013, 272:67-76.
68. Zhou D.S., Afzelius L., Grimm S.W., Andersson T.B., Zauhar R.J., Zamora I. Comparison of methods for the prediction of the metabolic sites for CYP3A4-mediated metabolic reactions. Drug Metab. Dispos. 2006, 34:976-983.